No they technically don’t, but the meeting also discussed the ‘Adult’ aGVHD trial progression and not just the Paeds aGVHD data and BLA.
I am keen to receive an update on the FDA’s thoughts on MSB’s methodology and progression of the trial. It also may give us more confirmation about MSB’s assay approach and FDA’s ongoing thoughts here.
If you know what I mean.
Mesoblast stock(rock)-take March 2024, page-138
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.01 | 94.3¢ | $8.618M | 8.821M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43508 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 34138 | 2 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |